AtriCure (NASDAQ:ATRC) announced its quarterly earnings data on Monday. The medical device company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.13, Briefing.com reports. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The company had revenue of $46.06 million for the quarter, compared to analyst estimates of $45.85 million. During the same quarter in the previous year, the company earned ($0.27) EPS. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year.
AtriCure (NASDAQ:ATRC) traded up $0.32 during mid-day trading on Tuesday, hitting $18.32. 163,000 shares of the stock were exchanged, compared to its average volume of 192,171. AtriCure has a 52 week low of $14.88 and a 52 week high of $25.18. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.65 and a current ratio of 2.28. The firm has a market cap of $620.53, a P/E ratio of -17.96 and a beta of 0.39.
In related news, SVP Justin J. Noznesky sold 4,000 shares of AtriCure stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $17.03, for a total transaction of $68,120.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO M. Andrew Wade sold 2,000 shares of AtriCure stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total value of $36,820.00. The disclosure for this sale can be found here. 11.90% of the stock is currently owned by company insiders.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.